{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-229480","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2024-10-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.206126+00:00","generated_at":"2026-05-30T23:28:54.405665+00:00","sec_items":["1.02","2.05","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Shattuck Labs discontinues SL-172154, cuts 40% workforce, pivots to DR3 antagonist SL-325","bullets":["Discontinued SL-172154 after interim OS data showed only modest improvement vs azacitidine monotherapy in TP53m AML/HR-MDS.","Plans to focus on SL-325, a first-in-class DR3 antagonist antibody for IBD; IND filing expected Q3 2025.","Approximately 40% workforce reduction; expects restructuring charges of $1.5M-$1.75M in Q4 2024.","Cash runway extended into 2027, with $105.3M cash, cash equivalents and investments as of June 30, 2024.","Mutually terminated collaboration with Ono Pharmaceutical; no future reimbursements, milestones, or royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-229480","json":"https://secwatch.observer/filing/0001193125-24-229480.json","markdown":"https://secwatch.observer/filing/0001193125-24-229480.md","text":"https://secwatch.observer/filing/0001193125-24-229480.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000119312524229480/0001193125-24-229480-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000119312524229480/d845252d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T23:28:54.405665+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}